科济药业-B(CARsgen Therapeutics)宣布,其候选药物CT1190b已获得中国国家药品监督管理局(NMPA)的临床试验(IND)许可。该药物将用于治疗复发或难治性大B细胞淋巴瘤(R/R LBCL)患者。
科济药业-B(CARsgen Therapeutics)宣布,其候选药物CT1190b已获得中国国家药品监督管理局(NMPA)的临床试验(IND)许可。该药物将用于治疗复发或难治性大B细胞淋巴瘤(R/R LBCL)患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.